Diabetic Retinopathy Clinical Research Network

Slides:



Advertisements
Similar presentations
The Diabetic Retinopathy Clinical Research Network One-Year Results from a Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for.
Advertisements

The Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema: Potential impact of.
(IRbesartan in MicroAlbuminuria, Type 2 Diabetic Nephropathy Trial)
Sponsored by the National Eye Institute,
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Macular Edema After Cataract Surgery Diabetic Retinopathy Clinical Research Network.
Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network Repeated Intravitreous Ranibizumab Injections for DME and Risk of Sustained IOP Elevation or Need for.
Henry N. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Diabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Study of Aflibercept, Bevacizumab, or Ranibizumab for DME Supported through a.
The Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network 5-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for.
Factors Associated with Changes in Visual Acuity and OCT Thickness at 1 Year after Treatment for Diabetic Macular Edema Sponsored by the National Eye Institute,
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
The Diabetic Retinopathy Clinical Research Network
Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema (DME) Part 3 A. Paul Chous, MA, OD, FAAO Specializing in Diabetes Eye Care & Education.
The Diabetic Retinopathy Clinical Research Network Protocol I: Clinical Applications Supported through a cooperative agreement from the National Eye Institute.
The Diabetic Retinopathy Clinical Research Network Expanded 2-year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: VEGFA and VEGFR1 and Response to Anti-VEGF Hagstrom SA, Ying G, Pauer GJT, et.
The Diabetic Retinopathy Clinical Research Network What is the Role of Laser In Treating Diabetic Macular Edema in the Era of Anti-VEGF Therapy? 1.
The Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
The Diabetic Retinopathy Clinical Research Network
Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health.
The Diabetic Retinopathy Clinical Research Network DRCR.net Prompt PRP vs Ranibizumab+Deferred PRP for PDR Study Jeffrey G. Gross, M.D. – Protocol Chair.
The Diabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
The Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year.
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Nephrology Journal Club The SPRINT Trial Parker Gregg
The Efficacy and Safety of the Low Intensity Ultrasound Treatment in Patients with Open Angle Glaucoma Hyoung Won Bae, Gong Je Seong, Chan Yun Kim Institute.
Section 4: Managing progression of CKD
The Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network
When Using DOPPS Slides
Exercise Adherence in Patients with Diabetes: Evaluating the role of psychosocial factors in managing diabetes Natalie N. Young,1, 2 Jennifer P. Friedberg,1,
From: Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2
The Diabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network
The Anglo Scandinavian Cardiac Outcomes Trial
The Diabetic Retinopathy Clinical Research Network
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Square-root TSH (μIU/mL) Presence vs. Absence TPO Abᵈ
Protocol U Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF.
Randomized Clinical Trial Jeffrey G. Gross, M.D. for the DRCR Network
DESIGN ISSUES OF A NON-INFERIORITY TRIAL
Systolic Blood Pressure Intervention Trial (SPRINT)
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The Diabetic Retinopathy Clinical Research Network
Baseline characteristics of HPS participants by prior diabetes
The Diabetic Retinopathy Clinical Research Network
Short-Term Evaluation of Combination
Diabetic Retinopathy Clinical Research Network
DRCRnet Rationale and Clinical Application of the DRCR.net Anti-VEGF Treatment Algorithm for Proliferative Diabetic Retinopathy Jennifer K. Sun, MD, MPH.
Diabetic Retinopathy Clinical Research Network
Prompt PRP vs. Ranibizumab + Deferred PRP for PDR Study
Diabetic Retinopathy Clinical Research Network
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
PowerPoint 16:9 Screen Ratio Template *
Pathway to initial antihypertensive therapy in patients with diabetes
The Diabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network
Presentation transcript:

Diabetic Retinopathy Clinical Research Network Plasma VEGF Concentrations after Intravitreous Anti-VEGF Therapy for DME During the DRCR.net Protocol-T   1

Financial Disclosures Funding/Support: Cooperative Agreement with NEI and NIDDK of NIH, U.S. Department of Health and Human Services. Additional Contributions: Regeneron Pharmaceuticals, Inc. provided the aflibercept; Genentech Inc. provided the ranibizumab. Genentech Inc. also provided funding for blood pressure cuffs and collection of plasma and urine that are not part of the main study reported herein A complete list of all DRCR.net investigator financial disclosures can be found at www.drcr.net. Personal Disclosures None

DRCR.net Protocol T

Objectives Pre-planned Secondary Analysis Assess the effect of intravitreous aflibercept, bevacizumab and ranibizumab on systemic free VEGF-A levels and compare the changes in levels across treatment groups

Methods Plasma samples collected at baseline, 4, 52 and 104 week visits prior to any ocular treatment Concentration of free VEGF* was measured in plasma using a commercial immunoassay Performed by an independent laboratory at the Fred Hutchinson Cancer Research Center where the samples were stored at -80°C Human VEGF Quantikine ELISA immunoassay (R&D Systems) 436 (66%) of all 660 Protocol T participants provided separate consent to participating in the plasma ancillary study. *2 duplicate readings were taken from each sample and the average of these measurements & the coefficient of variation (CV) was calculated. Only samples with CV < 20% (n=16 excluded) were included. A minimum quantifiable VEGF concentration of 7.8 pg/ml was used. VEGF concentration was analyzed using a natural log scale (ln) as recommended by the DRCR.net lead statistician (D. Liu and M. Melia) as the values were positively skewed. Change in VEGF concentration was truncated at 3 standard deviations from the mean pooling all treatments and visits (n=16 truncated). 436 (66%) of all 660 Protocol T participants provided separate consent to participating in the plasma ancillary study.

Change in Plasma VEGF Concentrations* * For the purpose of analysis, only samples with a CV less than 20% were included. VEGF concentrations were truncated at 7.8 pg/ml and were analyzed in the natural log scale (ln) since the values were positively skewed. To minimize the impact of extreme outliers, the mean change from baseline was truncated at 3 standard deviations from the mean pooling all treatments and visits.

Mean Plasma VEGF Concentrations Afl Bev Ran N = 139 N = 130 N = 141 Baseline (pg/ml) 28.50 31.45 37.55 4 weeks (pg/ml) 23.44 24.06 30.43 - The data on this slide only include patients with data at BL and week 4 (both visits). P-values adjusted for baseline ln(VEGF) concentration and multiple treatment group comparisons. Only including participants with available data at both baseline and 4-week visit ln(VEGF) = natural log of VEGF measurement

Mean Plasma VEGF Concentrations & Change from Baseline to Week 4 P = 0.89 (A v. B) P < 0.001 (A v. R) P < 0.001 (R v. B) Afl Bev Ran N = 139 N = 130 N = 141 Baseline (pg/ml) 28.50 31.45 37.55 4 weeks (pg/ml) 23.44 24.06 30.43 Change ln(VEGF) -0.30 -0.31 -0.02 - The data on this slide only include patients with data at BL and week 4 (both visits). P-values adjusted for baseline ln(VEGF) concentration and multiple treatment group comparisons. Only including participants with available data at both baseline and 4-week visit ln(VEGF) = natural log of VEGF measurement

Plasma VEGF Concentration Change in Plasma VEGF Concentrations Baseline to Week 52 for All Patients P = 0.07 (A v. B) P = 0.07 (A v. R) P < 0.001 (B v. R) Plasma VEGF Concentration Afl Bev Ran N = 132 N = 115 N = 130 Baseline (pg/ml) 28.10 31.69 33.47 52 weeks (pg/ml) 26.40 27.05 34.89 Change ln(VEGF) -0.10 -0.24 -0.03 P-values adjusted for baseline ln(VEGF) concentration and multiple treatment group comparisons. Only including participants with available data at both baseline and 52-week visit ln(VEGF) = natural log of VEGF measurement

No Injection within 1 month Yes Injections within 1 month Change in Plasma VEGF Concentrations Baseline to Week 52 by Timing of Injection No Injection within 1 month (N = 76 / 70 / 82 = 60%) P = 0.78 (A vs. B) P = 0.95 (A vs. R) P = 0.78 (B vs. R) Yes Injections within 1 month (N = 56 / 45 / 48) P = 0.03 (A vs. B) P = 0.003 (A vs. R) P < 0.001 (B vs. R) In order to be included in the analysis, the patient must have a 52-week sample, which means he/she must complete the 52-week visit. 52-week cohort N=377 [132/115/130 for A/B/R]: NO injection 1 month N=228 (60%) [76 (58%)/70 (61%)/82 (63%) for A/B/R], YES injection 1 month N=149 (40%) [56 (42%)/45 (39%)/48 (37%) for A/B/R] Change in ln(VEGF) Concentration +0.03 -0.07 -0.04 -0.28 -0.51 -0.03 P-values adjusted for baseline ln(VEGF) concentration and multiple treatment group comparisons. Only including participants with available data at both baseline and 52-week visit

No Injection within 2 months Yes Injections within 2 months Change in Plasma VEGF Concentrations Baseline to Week 52 by Timing of Injection No Injection within 2 months (N = 43 / 42 / 50 = 36%) P = 0.43 (A vs. B) P = 0.79 (A vs. R) P = 0.44 (B vs. R) Yes Injections within 2 months (N = 89 / 73 / 80) P = 0.15 (A vs. B) P = 0.02 (A vs. R) P < 0.001 (B vs. R) In order to be included in the analysis, the patient must have a 52-week sample, which means he/she must complete the 52-week visit. 52-week cohort N=377 [132/115/130 for A/B/R]: NO injection 2 months N=135 (36%) [43 (33%)/42 (37%)/50 (38%) for A/B/R], YES injection 2 months N=242 (64%) [89 (67%)/73 (63%)/80 (62%) for A/B/R] Change in ln(VEGF) Concentration +0.09 -0.06 +0.05 -0.20 -0.35 -0.09 P-values adjusted for baseline ln(VEGF) concentration and multiple treatment group comparisons. Only including participants with available data at both baseline and 52-week visit

Objectives & Methods Pre-planned Secondary Analysis Evaluate for a correlation between plasma VEGF levels and key systemic factors Adverse Events Recorded prospectively Mean Arterial Pressure (MAP) Calculated from 3 sets of BP at baseline, 4, 52 & 104 week visits Urine ACR Albumin-creatinine ratios calculated from urine samples* at baseline & 52-week visits Urine samples were collected at baseline and 52-week visits and were frozen at -20°C and shipped within 7 days of collection to the Advanced Research and Diagnostic Laboratory at the University of Minnesota for measurement of urinary albumin and creatinine Urine samples were frozen at -20°C and shipped within 7 days of collection to the Advanced Research and Diagnostic Laboratory at the University of Minnesota for measurement of urinary albumin and creatinine *Urine samples were frozen at -20°C and shipped within 7 days of collection to the Advanced Research and Diagnostic Laboratory at the University of Minnesota for measurement of urinary albumin and creatinine

Occurrence of APTC Events Through 52 Weeks Aflibercept Bevacizumab Ranibizumab Total No. of Participants* 132 115 130 377 Non-fatal MI 2 1 3 Non-fatal Stroke 4 Any APTC Event 7 * Only including participants with available plasma VEGF data at both baseline and 52-week visit

VEGF Concentration by APTC Event Through 52 Weeks * Only including participants with available plasma VEGF data at both baseline and 52-week visit

VEGF Concentration & Mean Arterial Pressure At Week 52 & Change from Baseline We did look at MAP vs. VEGF levels at each of the plasma sample collection visits. There was no significant correlation identified. The figure above on the left shows 52-week MAP vs. 52-week VEGF, and 52-week MAP change vs. 52-week VEGF log change on the right.

VEGF Concentration & Urine Albumin-Creatinine Ratio: At 52 Weeks Urine ACR No-albuminuria (N = 133) UACR < 30 pg/g Microalbuminuria (N = 112) 30 ≤ UACR ≤ 300 pg/g Macroalbuminuria (N = 128) UACR > 300 pg/g - We did look at the baseline VEGF by baseline UACR subgroups. No significant difference was identified (P=0.83) P=0.09 from Analysis of Variance, combing all treatment groups

Limitations Plasma VEGF levels only measured at 4 points Blood levels of the anti-VEGF agents not measured Assay uncertainties Systemic half lives of the drugs differ with ranibizumab cleared fastest Uncertainties over whether VEGF levels can be measured reliably in the presence of competing VEGF binding agents Protocol T not designed or powered to study systemic complications

Conclusions At 4 weeks, the decreases in VEGF levels were greater with aflibercept and bevacizumab compared with ranibizumab. This was still true for bevacizumab at 1 and 2 years, but not for aflibercept. In the pre-specified subgroups who did not receive an injection within 1 month prior to week 52, no differences in changes in VEGF levels were identified among anti-VEGF agents In patients who had received an injection within 1 or 2 months prior to the 52 week visit, the decreases in VEGF levels were less with ranibizumab than the other two drugs.

Conclusions There are no data from this analysis to suggest that patients with lower or higher VEGF plasma levels were at an increased risk of complications, but complication rates were low & samples were not necessarily obtained in proximity to the event